VolitionRX’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of VolitionRX (NYSEAMERICAN:VNRX) in a research report report published on Thursday morning,Benzinga reports. D. Boral Capital currently has a $3.00 price target on the medical research company’s stock.

Separately, Maxim Group lowered VolitionRX from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, VolitionRX currently has an average rating of “Buy” and an average price target of $2.50.

VolitionRX Stock Performance

Shares of VNRX stock opened at $0.19 on Thursday. The stock’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.35. VolitionRX has a twelve month low of $0.17 and a twelve month high of $0.94. The company has a market capitalization of $26.17 million, a price-to-earnings ratio of -0.84 and a beta of 1.33.

Hedge Funds Weigh In On VolitionRX

Institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in shares of VolitionRX during the second quarter valued at $52,000. Armistice Capital LLC boosted its stake in shares of VolitionRX by 3.5% in the 2nd quarter. Armistice Capital LLC now owns 8,493,074 shares of the medical research company’s stock valued at $6,455,000 after purchasing an additional 286,644 shares during the last quarter. Silverberg Bernstein Capital Management LLC boosted its stake in shares of VolitionRX by 15.6% in the 3rd quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the medical research company’s stock valued at $157,000 after purchasing an additional 31,300 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of VolitionRX during the 3rd quarter worth approximately $28,000. Finally, Citadel Advisors LLC grew its position in shares of VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after buying an additional 135,775 shares during the period. 8.09% of the stock is owned by institutional investors.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.